Head and neck cancer patient-derived xenograft models – A systematic review

[Display omitted] •This is the first systematic review that summarizes the use of HNC-PDX.•In general, the studies were flawed in terms of detailing the procedures used.•PDX recapitulates the histology and molecular aspects of the original HNC tumor.•PDX represents a valuable method in translational...

Full description

Saved in:
Bibliographic Details
Published inCritical reviews in oncology/hematology Vol. 155; p. 103087
Main Authors Schuch, Lauren F., Silveira, Felipe M., Wagner, Vivian P., Borgato, Gabriell B., Rocha, Guilherme Z., Castilho, Rogerio M., Vargas, Pablo A., Martins, Manoela D.
Format Journal Article
LanguageEnglish
Published Elsevier B.V 01.11.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:[Display omitted] •This is the first systematic review that summarizes the use of HNC-PDX.•In general, the studies were flawed in terms of detailing the procedures used.•PDX recapitulates the histology and molecular aspects of the original HNC tumor.•PDX represents a valuable method in translational research for the HNC. Patient-derived xenograft (PDX) involve the direct surgical transfer of fresh human tumor samples to immunodeficient mice. This systematic review aimed to identify publications of head and neck cancer PDX (HNC-PDX) models, describing the main methodological characteristics and outcomes. An electronic search was undertaken in four databases, including publications having used HNC-PDX. Data were analyzed descriptively. 63 articles were yielded. The nude mouse was one most commonly animal model used (38.8 %), and squamous cell carcinoma accounted for the majority of HNC-PDX (80.6 %). Tumors were mostly implanted in the flank (86.3 %), and the latency period ranged from 30 to 401 days. The successful rate ranged from 17 % to 100 %. Different drugs and pathways were identified. HNC-PDX appears to significantly recapitulate the morphology of the original HNC and represents a valuable method in translational research for the assessment of the in vivo effect of novel therapies for HNC.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Feature-4
ObjectType-Undefined-1
content type line 23
ObjectType-Review-2
ObjectType-Article-3
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2020.103087